• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单剂量卡格列净对健康冰岛马的药代动力学及血糖和胰岛素水平的影响

Pharmacokinetics and Alterations in Glucose and Insulin Levels After a Single Dose of Canagliflozin in Healthy Icelandic Horses.

作者信息

Michanek Peter, Bröjer Johan, Lilliehöök Inger, Fjordbakk Cathrine T, Löwgren Minerva, Hedeland Mikael, Bergquist Jonas, Ekstrand Carl

机构信息

Department of Animal Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden.

Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden.

出版信息

J Vet Pharmacol Ther. 2025 Jan;48 Suppl 1(Suppl 1):41-49. doi: 10.1111/jvp.13476. Epub 2024 Aug 7.

DOI:10.1111/jvp.13476
PMID:39113254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11736998/
Abstract

Canagliflozin (CFZ) is a sodium-glucose cotransporter-2 inhibitor that has shown promising results as a drug for the treatment of insulin dysregulation in horses. Even though CFZ is used clinically, no pharmacokinetic data has previously been published. In this study, the pharmacokinetics of CFZ after administration of a single oral dose of 1.8 mg/kg in eight healthy Icelandic horses was examined. Additionally, the effect of treatment on glucose and insulin levels in response to a graded glucose infusion was investigated. Plasma samples for CFZ quantification were taken at 0, 0.33, 0.66, 1, 1.33, 1.66, 2, 2.33, 2.66, 3, 3.5, 4, 5, 6, 8, 12, 24, 32, and 48 h post administration. CFZ was quantified using UHPLC coupled to tandem quadrupole mass spectrometry (UHPLC-MS/MS). A non-compartmental analysis revealed key pharmacokinetic parameters, including a median T of 7 h, a C of 2350 ng/mL, and a t of 28.5 h. CFZ treatment reduced glucose (AUC, p = 0.001) and insulin (AUC, p = 0.04) response to a graded glucose infusion administered 5 h after treatment. This indicates a rapid onset of action following a single dose in healthy Icelandic horses. No obvious adverse effects related to the treatment were observed.

摘要

卡格列净(CFZ)是一种钠-葡萄糖协同转运蛋白2抑制剂,已显示出作为治疗马匹胰岛素调节异常药物的良好效果。尽管CFZ已在临床上使用,但此前尚未发表过药代动力学数据。在本研究中,检测了8匹健康冰岛马单次口服1.8 mg/kg剂量后CFZ的药代动力学。此外,还研究了治疗对分级葡萄糖输注后血糖和胰岛素水平的影响。给药后0、0.33、0.66、1、1.33、1.66、2、2.33、2.66、3、3.5、4、5、6、8、12、24、32和48小时采集用于CFZ定量的血浆样本。使用超高效液相色谱-串联四极杆质谱联用仪(UHPLC-MS/MS)对CFZ进行定量。非房室分析揭示了关键的药代动力学参数,包括中位达峰时间为7小时、峰浓度为2350 ng/mL、消除半衰期为28.5小时。CFZ治疗降低了治疗后5小时给予的分级葡萄糖输注后的血糖(曲线下面积,p = 0.001)和胰岛素(曲线下面积,p = 0.04)反应。这表明在健康冰岛马中单次给药后起效迅速。未观察到与治疗相关的明显不良反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d374/11736998/ec3feab1941f/JVP-48-41-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d374/11736998/0303cb562047/JVP-48-41-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d374/11736998/55807ed0bcdb/JVP-48-41-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d374/11736998/ec3feab1941f/JVP-48-41-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d374/11736998/0303cb562047/JVP-48-41-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d374/11736998/55807ed0bcdb/JVP-48-41-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d374/11736998/ec3feab1941f/JVP-48-41-g003.jpg

相似文献

1
Pharmacokinetics and Alterations in Glucose and Insulin Levels After a Single Dose of Canagliflozin in Healthy Icelandic Horses.单剂量卡格列净对健康冰岛马的药代动力学及血糖和胰岛素水平的影响
J Vet Pharmacol Ther. 2025 Jan;48 Suppl 1(Suppl 1):41-49. doi: 10.1111/jvp.13476. Epub 2024 Aug 7.
2
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.单剂量卡格列净在健康中国受试者中的药代动力学、药效学及安全性
Clin Ther. 2015 Jul 1;37(7):1483-1492.e1. doi: 10.1016/j.clinthera.2015.04.015. Epub 2015 Jun 3.
3
Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.钠-葡萄糖协同转运蛋白2选择性抑制剂卡格列净在健康印度受试者中的单剂量药代动力学和药效学研究
Clin Ther. 2016 Jan 1;38(1):89-98.e1. doi: 10.1016/j.clinthera.2015.11.008. Epub 2015 Dec 11.
4
Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.卡格列净(钠-葡萄糖协同转运蛋白 2 抑制剂)的食物影响及其在健康受试者中的剂量比例评估。
Clin Pharmacol Drug Dev. 2015 Jul;4(4):279-86. doi: 10.1002/cpdd.151. Epub 2014 Dec 11.
5
Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.钠-葡萄糖协同转运蛋白2抑制剂卡格列净的临床药代动力学、药效学及药物相互作用特征
Clin Pharmacokinet. 2015 Oct;54(10):1027-41. doi: 10.1007/s40262-015-0285-z.
6
Enhanced oral bioavailability and anti-diabetic activity of canagliflozin through a spray dried lipid based oral delivery: a novel paradigm.通过喷雾干燥脂质基口服递送来提高坎格列净的口服生物利用度和抗糖尿病活性:一种新的范例。
Daru. 2020 Jun;28(1):191-208. doi: 10.1007/s40199-020-00330-3. Epub 2020 Feb 7.
7
Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants.卡格列净的绝对口服生物利用度和药代动力学:健康参与者的微剂量研究。
Clin Pharmacol Drug Dev. 2015 Jul;4(4):295-304. doi: 10.1002/cpdd.162. Epub 2014 Dec 11.
8
Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.卡格列净在日本2型糖尿病患者中的药代动力学、药效学及安全性
Adv Ther. 2015 Aug;32(8):768-82. doi: 10.1007/s12325-015-0234-0. Epub 2015 Aug 18.
9
A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State.一项评估 DJT1116PG(一种新型选择性钠-葡萄糖共转运蛋白 2 抑制剂)在稳态健康人群中药代动力学和药效学的 I 期研究。
Clin Ther. 2020 May;42(5):892-905.e3. doi: 10.1016/j.clinthera.2020.03.007. Epub 2020 Apr 4.
10
A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats.一种经过验证的液相色谱-串联质谱法,用于在较少量大鼠血浆中测定钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂卡格列净:应用于大鼠药代动力学研究。
Biomed Chromatogr. 2016 Oct;30(10):1549-55. doi: 10.1002/bmc.3720. Epub 2016 Apr 13.

本文引用的文献

1
Short-term effects of canagliflozin on glucose and insulin responses in insulin dysregulated horses: A randomized, placebo-controlled, double-blind, study.卡格列净对胰岛素失调马葡萄糖和胰岛素反应的短期影响:一项随机、安慰剂对照、双盲研究。
J Vet Intern Med. 2023 Nov-Dec;37(6):2520-2528. doi: 10.1111/jvim.16906. Epub 2023 Oct 21.
2
The effect of pre-dosing with metformin on the insulin response to oral sugar in insulin-dysregulated horses.二甲双胍预给药对胰岛素调节异常马匹口服糖的胰岛素反应的影响。
Equine Vet J. 2024 Mar;56(2):318-325. doi: 10.1111/evj.13979. Epub 2023 Aug 6.
3
Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors.
马伴难治性高胰岛素血症的高甘油三酯血症用 SGLT2 抑制剂治疗。
Open Vet J. 2023 Mar;13(3):365-375. doi: 10.5455/OVJ.2023.v13.i3.14. Epub 2023 Mar 20.
4
Identifying possible thresholds for nonstructural carbohydrates in the insulin dysregulated horse.鉴定胰岛素失调马中非结构性碳水化合物的可能阈值。
Equine Vet J. 2023 Nov;55(6):1069-1077. doi: 10.1111/evj.13910. Epub 2023 Jan 23.
5
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.9. 血糖治疗的药物学方法:2023 年糖尿病的护理标准。
Diabetes Care. 2023 Jan 1;46(Suppl 1):S140-S157. doi: 10.2337/dc23-S009.
6
Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis.使用 SGLT2 抑制剂卡格列净控制难治性马属动物高胰岛素血症和蹄叶炎。
Open Vet J. 2022 Jul-Aug;12(4):511-518. doi: 10.5455/OVJ.2022.v12.i4.14. Epub 2022 Aug 7.
7
Postprandial insulin responses to various feedstuffs differ in insulin dysregulated horses compared with non-insulin dysregulated controls.与非胰岛素失调对照相比,胰岛素失调马对各种饲料的餐后胰岛素反应不同。
Equine Vet J. 2022 May;54(3):574-583. doi: 10.1111/evj.13474. Epub 2021 Jul 8.
8
Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review.胃肠道变异性对口服药物吸收和药代动力学的影响:UNGAP 综述。
Eur J Pharm Sci. 2021 Jul 1;162:105812. doi: 10.1016/j.ejps.2021.105812. Epub 2021 Mar 20.
9
Enterohepatic circulation of glucuronide metabolites of drugs in dog.药物葡萄糖醛酸代谢物在狗体内的肠肝循环。
Pharmacol Res Perspect. 2019 Jul 4;7(4):e00502. doi: 10.1002/prp2.502. eCollection 2019 Aug.
10
The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies.维格列净治疗小马胰岛素调节异常16周的疗效和安全性。
BMC Vet Res. 2019 Feb 26;15(1):65. doi: 10.1186/s12917-019-1811-2.